Bolt Biotherapeutics, Inc. (BOLT) stock
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 11/3034% below fair value
$5.91−0.35 (-5.59%)
Close on Nov 12, 2026Market cap $11.38MP/E –Yield –
Bolt Biotherapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
No gross margin figures for Bolt Biotherapeutics
Bolt Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?